September 6, 2019
Grifols and Mondragon sign technology collaboration agreement
- The companies will combine efforts in medical and pharmaceutical technology including robotics and instrumentation as part of a long-term agreement.
- Joint Action Committee to prioritize projects and resources.
Barcelona and Mondragón, Spain, Sept. 6, 2019 – Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the production of plasma-derived medicines, and Mondragon, a worldwide leader in work cooperation and one of Spain’s most relevant business groups, today announced an agreement to jointly develop healthcare sector-related automation, robotics and instrumentation as well as other technologies and infrastructure.
The agreement also includes training and talent collaborations linked to the university of the Basque industrial group.
A Joint Action Committee comprised of members from both companies will identify and prioritize initial projects over the next few months.
“Grifols is exceptionally pleased to collaborate with a highly renown technology and industrial leader such as the Mondragon group. The agreement represents an opportunity to jointly develop innovative technology solutions for the medical and pharmaceutical sectors, particularly projects related to instrumentation and robotics, which are constantly changing,” said Victor Grifols Deu and Raimon Grifols, co-CEOs of Grifols.
“For Mondragon it’s enormously satisfying to sign this collaboration agreement with Grifols after many years of a positive relationship. The framework agreement is designed to drive innovation and new businesses in strategic areas such as health,” said Iñigo Ucin, president of Mondragon.